A new mutual-fund-like investment vehicle takes the idea of niche investing to an even higher level, The Wall Street Journal reports. The Violts, or Veritcal Investments of Life Sciences Trusts, are unit investment trusts that will invest in companies that try to cure some of the world’s deadliest diseases.

New Orleans-based Doley Securities last month started offering the Violts, which will invest in small biotechnology companies, large pharmaceutical firms and industrial companies that sell medical equipment. Many of the firms involved are working on cures to diseases like Alzheimer’s and breast cancer.

Subscribe Now

Access to premium content including in-depth coverage of mutual funds, hedge funds, 401(K)s, 529 plans, and more.

3-Week Free Trial

Insight and analysis into the management, marketing, operations and technology of the asset management industry.